Treatment Information

Back

Ovarian Cancer treatment details. Biologic therapy.

Princess Margaret Hospital, Toronto, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:4City/State/Province:Toronto
Treatments:Biologic therapyHospital:Princess Margaret Hospital
Drugs:Journal:Link
Date:May 2007

Description:

Patients: This phase II study evaluated 29 women with advanced recurrent ovarian cancer. The median age was 55 years, ranging from 23 to 72. All had received a previous chemotherapy regimen that included carboplatin or cisplatin.

Treatment: All patients were treated with biological therapies topotecan and UCN-01. Topotecan and UCN-01 are cytotoxic (cell-killing).

Toxicity: The most common grade 3 and 4 toxicities were hematological (neutropenia, anemia, thrombocytopenia), hypoglycemia, and pain.

Results: The median overall survival was 9.7 months. The authors concluded that the “combination of topotecan with UCN-01 was tolerated reasonable well…but did not appear to have sufficient antitumor activity in this patient population to warrant further study.”

Correspondence: Dr. Hal Hirte





Back